30 closest matches · ranked by relevance
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Brain and Central Nervous System Tumors
Primary: Progression-free Survival Rate at 3 Years — 92.2; 93.7; 58.8 percentage of participants
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Adult Grade I Meningioma · Adult Grade II Meningioma · Adult Grade III Meningioma
Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Meningioma
Primary: Intraoperative Blood Loss — 510; 500 ml — p=0.315
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Acoustic Schwannoma · Adult Anaplastic Meningioma · Adult Ependymoma
Primary: Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months — 93; 85; 51; 73 percentage of patients
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Glioblastoma · Gliosarcoma
Primary: Progression-free Survival at 6 Months — 61.9 percentage of participants
Meningioma
Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…
Adult Meningioma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 Participants
Hemostasis · Meningioma Surgery
Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
High Grade Glioma
Primary: Response Rate
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants
Malignant Glioma
Primary: Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT) — 0; 0 Participants
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Brain Tumor, Primary
Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Glioma
Primary: Progression-free Survival
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…